U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Google Secures Pentagon AI Deal for Classified Projects 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
LOS ANGELES, May 08, 2017 -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (NYSE MKT:IMUC) concerning possible violations of federal securities laws between May 1, 2012 and December 11, 2013 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the June 30, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, ImmunoCellular issued materially false and/or misleading statements and/or failed to disclose: that ImmunoCellular retained Lidingo Holdings, LLC to publish promotional articles designed to unlawfully promote the Company; and that as a result of this scheme, the market was led to believe that the Company’s clinical studies for its product candidate ICT-107 was going well and the share price was artificially inflated. When this news reached the public, the Company’s stock price dropped materially, which harmed investors according to the Complaint. On April 10, 2017, the Securities and Exchange Commission announced enforcement actions against numerous individuals and entities, including ImmunoCellular, which engaged in stock promotion schemes.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
